Researcher | Theodor Bilharz Research Institute | Egypt
She is an accomplished oncology and molecular biology researcher with a strong interdisciplinary profile spanning cancer biology, biotechnology, pharmacology, and translational therapeutics. With more than 355 citations, an h-index of 12, and an i10-index of 14, her work demonstrates sustained scientific impact and relevance before and after 2020. Her research focuses on molecular mechanisms underlying cancer progression and therapy, particularly hepatocellular carcinoma and colon cancer, with emphasis on apoptosis, autophagy, tumor suppressor signaling, and immune modulation. She has made notable contributions to peptide-based anticancer strategies, including recombinant expression of bioactive peptides such as Cecropin-B and Chromogranin A derivatives, showing promising therapeutic potential against resistant cancer cell lines. Her expertise extends to molecular cloning, gene expression analysis, and recombinant protein production in bacterial systems, supporting both diagnostic and therapeutic innovation. In parallel, she has contributed to studies on gut microbiota modulation, metabolic disorders linked to cancer risk, antiviral and antibacterial nanotechnologies, and natural product–derived anticancer compounds, reflecting a broad translational vision. As a verified researcher affiliated with Theodor Bilharz Research Institute, she actively collaborates with senior professors and multidisciplinary teams across biochemistry, pharmacology, pathology, and biotechnology. Her publications in high-impact journals such as Bioorganic Chemistry, European Journal of Pharmacology, Life Sciences, Molecular Biology Reports, and Current Pharmaceutical Biotechnology highlight her ability to integrate in vitro, in silico, and molecular approaches to address complex biomedical challenges. Beyond oncology, her work contributes to antimicrobial resistance solutions, immunotherapy-related biomarkers, and environmentally responsive molecular systems. Overall, her scientific profile reflects a dedicated researcher advancing cancer therapeutics and molecular medicine through innovative experimental design, strong collaborative networks, and a clear commitment to translational and societal impact.
Featured Publications
Ahmed, L. A., Salem, M. B., Seif el-Din, S. H., El-Lakkany, N. M., Ahmed, H. O., Nasr, S. M., et al. (2020). Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways. European Journal of Pharmacology, 887, 173461.
Samir, S., El-Far, A., Okasha, H., Mahdy, R., Samir, F., & Nasr, S. M. (2022). Isolation and characterization of lytic bacteriophages from sewage at an Egyptian tertiary care hospital against methicillin-resistant Staphylococcus aureus clinical isolates. Saudi Journal of Biological Sciences, 29(5), 3097–3106.
Abdelmonsef, A. H., Abdelhakeem, M. A., Mosallam, A. M., Temairk, H., Okasha, H., et al. (2022). A search for anti-inflammatory therapies: Synthesis, in silico investigation of the mode of action, and in vitro analyses of new quinazolin-2,4-dione derivatives targeting inflammatory pathways. Journal of Heterocyclic Chemistry, 59(3), 474–492.
Morsi, E. A., Ahmed, H. O., Abdel-Hady, H., El-Sayed, M., & Shemis, M. A. (2020). GC-analysis, antioxidant, anti-inflammatory, and anticancer activities of some extracts and fractions of Linum usitatissimum. Current Bioactive Compounds, 16(9), 1309–1318.
Seif el-Din, S. H., Salem, M. B., El-Lakkany, N. M., Hammam, O. A., Nasr, S. M., et al. (2021). Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. Human & Experimental Toxicology, 40(9), 1496–1509.
Her work advances oncology and molecular medicine by translating peptide-based therapeutics, microbiome modulation, and recombinant biotechnology into promising anticancer and antimicrobial strategies. By integrating molecular biology, pharmacology, and nanotechnology, her research addresses cancer treatment resistance and infectious disease challenges with strong potential for clinical and industrial translation.